Oka Masahiro, Hitomi Tomohiro, Okada Taro, Nakamura Si Shun-ichi, Nagai Hiroshi, Ohba Motoi, Kuroki Toshio, Kikkawa Ushio, Ichihashi Masamitsu
Department of Dermatology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Biochem Biophys Res Commun. 2002 Jun 28;294(5):1109-13. doi: 10.1016/S0006-291X(02)00614-9.
The regulation of phospholipase D1 (PLD1), which has been shown to be activated by protein kinase C (PKC) alpha, was investigated in the human melanoma cell lines. In G361 cell line, which lacks PKCalpha, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced PLD activation was potentiated by introducing PKCalpha by the adenovirus vector. The kinase-negative PKCalpha elevated TPA-induced PLD activity less significantly than the wild type. A PKC specific inhibitor GF109203X lowered PLD activation in the cells expressing PKCalpha, but did not prevent PLD potentiation induced by the kinase-negative PKCalpha. Expression of PKCbetaII and the kinase-negative PKCbetaII enhanced TPA-stimulated PLD activity moderately in MeWo cell line, in which PKCbetaII is absent. Furthermore, the TPA treatment increased the association of PKCalpha, PKCbetaII, and their kinase-negative mutants with PLD1 in melanoma cells. These results indicate that PLD1 is dually regulated through phosphorylation as well as through the protein-protein interaction by PKCalpha, and probably by PKCbetaII, in vivo.
在人黑色素瘤细胞系中研究了磷脂酶D1(PLD1)的调节作用,该酶已被证明可被蛋白激酶C(PKC)α激活。在缺乏PKCα的G361细胞系中,通过腺病毒载体导入PKCα可增强12 - O - 十四酰佛波醇 - 13 - 乙酸酯(TPA)诱导的PLD激活。激酶阴性的PKCα增强TPA诱导的PLD活性的程度不如野生型显著。PKC特异性抑制剂GF109203X降低了表达PKCα的细胞中的PLD激活,但不能阻止激酶阴性的PKCα诱导的PLD增强。在缺乏PKCβII的MeWo细胞系中,PKCβII及其激酶阴性突变体的表达适度增强了TPA刺激的PLD活性。此外,TPA处理增加了黑色素瘤细胞中PKCα、PKCβII及其激酶阴性突变体与PLD1的结合。这些结果表明,在体内,PLD1通过PKCα以及可能通过PKCβII的磷酸化和蛋白质 - 蛋白质相互作用受到双重调节。